Patent details

Basic Information

Publication number:

EP3173084

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP162017156

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES

French Title of Invention:

DÉRIVÉS DE QUINAZOLINE POUR LE TRAITEMENT DE CANCERS

German Title of Invention:

CHINAZOLINDERIVATE ZUR BEHANDLUNG VON KREBSERKRANKUNGEN

SPC Number:

Dates

Filing date:

09/11/2006

Grant date:

23/10/2019

EP Publication Date:

31/05/2017

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

23/10/2019

EP B1 Publication Date:

23/10/2019

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

09/11/2019

Expiration date:

09/11/2026

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

16/10/2019

 

 

Name:

Boehringer Ingelheim International GmbH

Address:

Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (DE)

Inventor

1

Name:

BAUM, Anke

Address:

Germany (DE)

2

Name:

SOLCA, Flavio

Address:

Germany (DE)

3

Name:

STEHLE, Gerd

Address:

Germany (DE)

4

Name:

VAN MEEL, Jacobus C. A.

Address:

Germany (DE)

5

Name:

AMELSBERG, Andree

Address:

Germany (DE)

Priority

Priority Number:

05110656

Priority Date:

11/11/2005

Priority Country:

European Patent Office (EPO) (EP)

Classification

IPC classification:

A61K 31/517; A61K 31/553; A61P 35/00;

Publication

European Patent Bulletin

Issue number:

201943

Publication date:

23/10/2019

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages